SCN5A Variant G35V
Summary of observed carriers, functional annotations, and structural context for SCN5A G35V. Data combine curated literature, international cohorts, and gnomAD observations.
Estimated LQT3 penetrance
4%
0/10 effective observations
Estimated BrS1 penetrance
6%
0/10 effective observations
Total carriers
0
0 BrS1 · 0 LQT3 · 0 unaffected
Variant features alone are equivalent to phenotyping 0 individuals for Brugada syndrome and 0 individuals for LQT3.
In silico predictors
PROVEAN | PolyPhen-2 | BLAST-PSSM | REVEL | Penetrance Density BrS (%) | Penetrance Density LQT3 (%) |
---|---|---|---|---|---|
NA | NA | NA | 0.286 | 2 | 4 |
PROVEAN scores below -2 suggest deleterious impact. REVEL scores above 0.5–0.75 are often interpreted as likely pathogenic. PolyPhen-2 scores above 0.85 are typically pathogenic. Penetrance density summarises neighbouring residue risk (Kroncke et al. 2019).
Reported carrier data
Source | Year | Carriers | Unaffected | LQT3 | BrS1 | Other | Other Disease |
---|---|---|---|---|---|---|---|
Literature, cohort, and gnomAD | – | 0 | 0 | 0 | 0 | – | |
Variant features alone | – | 15 | 15 | 0 | 0 | – | – |
Totals may differ from individual publications due to duplicate patients removed during curation.
Nearby variants
Neighbouring residues within 15 Ångström provide structural context. Variants listed in the right-most column have been observed clinically or in gnomAD.
Neighbour residue | Distance (Å) | Observed variants |
---|---|---|
20 | 15 | S20F, |
21 | 14 | L21V, |
22 | 14 | A22V, |
23 | 13 | A23S, |
24 | 13 | |
25 | 12 | E25K, |
26 | 11 | |
27 | 11 | R27L, R27H, R27C, |
28 | 10 | M28T, M28L, M28I, M28I, M28L, M28I, |
29 | 9 | A29V, A29E, |
30 | 8 | E30G, |
31 | 8 | |
32 | 7 | |
33 | 5 | |
34 | 4 | R34C, R34H, |
35 | 0 | G35S, |
36 | 4 | |
37 | 5 | T37A, |
38 | 7 | |
39 | 8 | L39F, L39F, |
40 | 8 | |
41 | 9 | |
42 | 10 | |
43 | 11 | R43Q, R43X |
44 | 11 | |
45 | 12 | G45A, |
46 | 13 | |
47 | 13 | |
48 | 14 | E48K, |
49 | 14 | E49K, |
50 | 15 |